Brief: India's Jubilant Life Sciences Dec-Qtr Consol Net Profit Rises
Feb 5 (Reuters) - Jubilant Life Sciences Ltd JULS.NS :
* DEC-QUARTER CONSOL NET PROFIT 3.1 BILLION RUPEES VERSUS
2.03
BILLION RUPEES YEAR AGO
* DEC-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 17.71
BILLION
RUPEES VERSUS 15.18 BILLION RUPEES YEAR AGO
* COVID-19 NOT LIKELY TO HAVE MATERIAL IMPACT ON PERFORMANCE
DURING FY21
* FOR LSI, SEES CLOSE TO DOUBLE-DIGIT REVENUE GROWTH,
SIGNIFICANT
EBITDA GROWTH IN FY21
* OVERALL, CONTINUE TO SEE STRONG PERFORMANCE IN Q4FY21
Source text for Eikon: ID:nBSE9psSLT
Further company coverage: JULS.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jubilant Pharmova
See all newsBrief: Jubilant Pharmova Sept-Quarter Consol Net Profit 312 Million Rupees
Brief: Jubilant Pharmova Says Jubilant Therapeutics Announces Oral Presentation Of Preliminary Phase 1 Clinical Data For JBI-802
India New Issue-Jubilant Pharmova to issue 3-year bonds, bankers say
India's Jubilant Pharmova eyes $150 mln through rupee debt sale, bankers say
Brief: Jubilant Pharmova To Consider Raising Of Funds Through Issuance Of Non- Convertible Debentures